Trumps New Drug Price Rule Targets 9 Drugmakers

President Donald Trump has secured new deals with nine major pharmaceutical companies. The agreements aim to lower prescription drug prices for Americans. The announcement was made at a White House press conference on Friday. This move is part of a broader effort to align U.S. drug costs with prices in other developed nations.

Trump Drug Prices Deal Targets Nine Major Manufacturers

The Trump administration has finalized agreements with nine leading drugmakers. The companies are Amgen, Boehringer Ingelheim, and Bristol Myers Squibb. The list also includes Genentech (Roche), Gilead, and GSK. Merck, Novartis, and Sanofi complete the group.

These deals bring the total to 14 companies with commitments. The administration initially pressured 17 manufacturers back in July. According to Reuters, similar arrangements were previously made with Pfizer and AstraZeneca. Eli Lilly and Novo Nordisk also agreed to terms earlier.

Three large firms have not yet finalized agreements. AbbVie, Johnson & Johnson, and Regeneron remain in discussions. A Regeneron spokesperson confirmed talks are ongoing. The goal is to prevent American consumers from subsidizing global drug costs.

President Trump emphasized this point clearly. He stated the U.S. would not continue funding lower prices abroad. The policy shift aims to create a more level international playing field.

How the New TrumpRx.gov Portal Will Work for Consumers

The centerpiece of this initiative is a new federal website. The TrumpRx.gov portal will direct consumers to manufacturer sites. There, patients can purchase medications directly without using insurance. A preview version of the site is already live online.

Full operations are expected to begin in January. The direct-purchase model is designed to increase price transparency. It allows patients to see and pay lower, internationally benchmarked costs upfront. This bypasses complex insurance negotiations and pharmacy benefit managers.

The agreements also cover public health programs. Companies will provide most products to state Medicaid systems at international prices. Medicaid already receives the lowest U.S. prices by law. Officials say the new deals will yield extra savings on specific drugs.

Manufacturers made another key promise. Future drugs launched in the U.S. will be priced in line with other wealthy nations. In return, the companies get a three-year exemption from potential pharmaceutical tariffs. This incentive is crucial for securing their participation.

Broader Impact of the Most Favored Nation Model

This policy is often called the “Most Favored Nation” approach. It ties U.S. drug payments to the lowest prices among similar countries. The model has been a longstanding goal of the administration. The Associated Press reports it represents a significant shift in federal drug pricing strategy.

The change could lower out-of-pocket costs for many Americans. It particularly affects those on Medicare and Medicaid. The policy also puts pressure on the remaining holdout companies. The administration hopes they will agree to terms soon.

Industry analysts are watching the rollout closely. The success of the TrumpRx.gov portal will be critical. Its user-friendliness and accessibility will determine consumer adoption. January’s full launch will be the first real test.

The new focus on Trump drug prices marks a concrete step toward cheaper prescriptions. The involvement of nine major manufacturers signals industry engagement. The coming months will reveal the real-world impact on American wallets.